HomeIndustriesHealthcareOzempic Impact On Davita (DVA) & Baxter (BAX)

Ozempic Impact On Davita (DVA) & Baxter (BAX)

Novo Nordisk (NVO) stopped the trial on the progression of renal impairment for people with Type 2 Diabetes and chronic kidney disease after Ozempic showed success in the study. George Tsilis discusses Ozempic’s impact on two other healthcare stocks Davita (DVA) and Baxter (BAX). Tune in to find out more about the stock market today.

Market On Close

11 Oct 2023

SHARE

ON AIR
education
2:30 am
Your First Trade
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
ON AIR
education
2:30 am
Your First Trade
REPLAY
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor